Neurol. praxi. 2014;15(1):16-21

Use of positron emission tomography in neurology

MUDr. Irena Doležalová1,2, MUDr. Karol Bolčák3, prof. MUDr. Robert Kuba, Ph.D.1,2
1 Centrum pro epilepsie Brno, I. neurologická klinika LF MU a FN u sv. Anny v Brně
2 Středoevropský technologický institut CEITEC, MU Brno
3 Oddělení nukleární medicíny a pozitronové emisní tomografie, Masarykův onkologický ústav, Brno

Positron emission tomography (PET) is an imaging technique providing information on the function of a certain tissue or organ. It is primarily used in oncology, neurology, and cardiology. The present review briefly explains the principle of PET examination and subsequently deals with its use in neurology. The main focus is on the fields of neuro-oncology and epileptology, i.e. on indications in which PET is commonly utilized clinically. Also mentioned are the options of its application in diagnosing extrapyramidal diseases, dementias, and cerebral infarctions; in these indications, PET is largely limited to the field of research.

Keywords: positron emission tomography (PET), neurology, neuro-oncology, dementia, extrapyramidal diseases, cerebral infarction

Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležalová I, Bolčák K, Kuba R. Use of positron emission tomography in neurology. Neurol. praxi. 2014;15(1):16-21.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DA, Sima AA. Fluro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996; 47: 462-466. Go to original source... Go to PubMed...
    2. Arnold S, Schlaug G, Niemann H, Ebner A, Lüders H, Witte OW, Seitz RJ. Topography of interictal glucose hypometabolism in unilateral mesiotemporal epilepsy. Neurology 1996; 46: 1422-130. Go to original source... Go to PubMed...
    3. Brázdil M, Mikl M, Chlebus P, Pažourková M, Novák Z, Chrastina J. Combining advancet neuroimaging technique in presurgical work-up of non-lesional intractable Epilepsy. Epileptic Disord 2006; 8: 190-194. Go to PubMed...
    4. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson´s disease. Neurology 1993; 43: S6-S16.
    5. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson´s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57: 278-284. Go to original source... Go to PubMed...
    6. Bybel B, Brunken RC, Shah SS, Guiyun W, Turbiner E, Neumann DR. PET and PET/CT imaging: What clinicians need to know? Cleveland Clinic Journal of Medicine 2006: 73: 1075-1087. Go to original source... Go to PubMed...
    7. De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotchi J, Goldman S. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2003; 97: 1056-1064.
    8. Drzezga A, Arnold S, Minoshima S, Noachtar S, Szecsi J, Winkler P, Römer W, Tatsch K, Weber W, Bartenstein P. 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med 1990; 79: 39-48.
    9. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, L?ngström B, Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006; 129: 2856-2866. Go to original source... Go to PubMed...
    10. Feeney DM, Baron JC. Diaschisis. Stroke 1986; 17: 817-830. Go to original source... Go to PubMed...
    11. Furlan M, Marchal G, Viader F, Derlon JM, Baron JC. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol 1996; 40: 2016-226. Go to original source... Go to PubMed...
    12. Guadagno JV, Calautti C, Baron JC. Progress in imaging stroke: emerging clinical applications. Brit Med Bull 2003; 65: 145-157. Go to original source... Go to PubMed...
    13. Heiss WD, Kracht LW, Thiel A, Grond M, Pawlik G. Penumbra probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain 2001; 124: 20-29. Go to original source... Go to PubMed...
    14. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord 1995; 9: 6-16. Go to original source... Go to PubMed...
    15. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010; 17: 1236-1248. Go to original source... Go to PubMed...
    16. Hort J. Nová guidelines pro diagnostiku a léčbu Alzheimerovy choroby. Neurol. praxi 2011; 12: 277-281.
    17. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbé C, Cunningham VJ, Koepp MJ, Hammers A, Morris RG, Turjanski N, Brooks DJ. Cortical dysfunction in non-demented Parkinson´s disease patients? A combined (31) P-MRS and (18) FDG-PET study. Brain 2000; 123: 340-352. Go to original source... Go to PubMed...
    18. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009; 132: 1355-1365. Go to original source... Go to PubMed...
    19. Juhasz C, Chugani DC, Muzik O, Shah A, Shah J, Watson C, Canady A, Chugani HT. Relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome. Neurology 2001; 56: 1650-1658. Go to original source... Go to PubMed...
    20. Kuba R, Tyrlíková I, Chrastina J, Slaná B, Pažourková M, Hemza J, Brázdil M, Novák Z, Hermanová M, Rektor I. "MRI-negative PET-positive" temporal lobe epilepsy: invasive EEG findings, histopathology, and postoperative outcomes. Epilepsy Behav 2011; 22: 537-541. Go to original source... Go to PubMed...
    21. Kudr M, Kršek P, Marusič P, Tomášek M, Trnak J, Michalová K. SISCOM and FDG-pet in patients with non-lesional extratemporal epilepsy: correlation with intracranial EEG, histology, and seizure outcome. Epileptic Disord 2013; 15: 3-13. Go to original source... Go to PubMed...
    22. La Fougére C, Rominger A, Főrster, Geisler J, Bartenstein. PET and SPECT in epilepsy: A critical review. Epilepsy Behav. 2009; 15: 50-55. Go to original source... Go to PubMed...
    23. LoPinto-Khoury C, Sperling MR, Skidmore C, Nei M, Evans J, Sharam A, Mintzer S. Surgical outcome in PET-positive, MRI negative patients with temporal lobe epilepsy. Epilepsia 2011; 53: 342-348. Go to original source... Go to PubMed...
    24. Marusič P, Tomášek M, Belšan T, Křížová H. Zobrazovací a funkčně-zobrazovací metody v epileptologii. Neurol. praxi 2002; 2: 73-75.
    25. Muzik O, da Silva EA, Juhasz C, Chugani DC, Shah J, Nagy F, Canady A, von Stockhausen HM, Herholz K, Gates J, Frost M, Ritter F, Watson C, Chugani HT. Intracranial EEG versus flumazenil and glucose PET in children with extratemporal lobe epilepsy. Neurology 2000; 54: 191-179. Go to original source... Go to PubMed...
    26. Nekula J. Algoritmus vyšetřování zobracovacími metodami u nádorů mozku, páteře a páteřního kanálu. Neurol. praxi 2003; 5: 229-235.
    27. Quigley H, Collogy J, O´Brien. PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry 2011; 26: 991-999. Go to original source... Go to PubMed...
    28. Rozental JM, Levine RL, Mehta MP, Kinsella TJ, Levin AB, Algan O, Mendoza M, Hanson JM, Schrader DA, Nickles RJ. Early chages in tumor metabolism after treatment: the effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 1991; 20: 1053-1060. Go to original source... Go to PubMed...
    29. Ryvlin P, Bouvard S, Le Bars D, De Lamérie G, Grégoire MC, Kahane P, Froment JC, Maugui?re F. Clinical utility of flumazenil-PET versus [18F] flurodeoxyglucose-PET and MRI in refractory partial epilepsy? A prospective study in 100 patients. Brain 1998; 121: 2067-2081. Go to original source... Go to PubMed...
    30. Rosenow F, Lüders H. Presurgical evaluation of epilepsy. Brain 2001;124:1683-1700. Go to original source... Go to PubMed...
    31. Salmon E. Functional brain imaging applications to differential diagnosis in dementias. Curr Opin Neurol 2002; 15: 439-444. Go to original source... Go to PubMed...
    32. Savic I, Svanborg E, Thorell JO. Cortical benzodiazepine receptor changes are related to frequency of partial seizures: a positron emission tomography study. Epilepsia 2000; 54: 171-179.
    33. Silverman DH, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W, Czernin J, Rapoport SI Pietrini P, Alexader GE, Schapiro MB, Jagust WJ,Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001; 288: 2120-2127. Go to original source... Go to PubMed...
    34. Tai YF, Piccini P. Applications of positron emission tomography (PET) in neurology. J Neurol Neurosurg Psychiatry 2004: 75: 669-676. Go to original source... Go to PubMed...
    35. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of clinical and subclinical tumor response using [18F] flurorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782. Go to original source... Go to PubMed...
    36. Vallabhajosula S. 18F-Labeled Positron Emission Tomographic Radiopharmaceuticals in Oncology: An Overview of Radiochemistry and Mechanisms of Tumor Localization. Semin Nucl Med 2007; 37: 400-419. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.